Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 16/20 | 0.45 |
| ▸ | F10 | P00742 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22685920 | 1.00 | KLKB1 (0.45) | KLKB1F10CYP1A2POLBCYP3A4 | |
| SCHEMBL20446649 | 1.00 | KLKB1 (0.45) | KLKB1F10CYP1A2POLBCYP3A4 | |
| SCHEMBL29489465 | 1.00 | KLKB1 (0.45) | KLKB1F10CYP1A2POLBCYP3A4 | |
| SCHEMBL20584552 | 0.93 | KLKB1 (0.46) | KLKB1F10 | |
| SCHEMBL20584548 | 0.93 | KLKB1 (0.46) | KLKB1F10 | |
| SCHEMBL20584550 | 0.93 | KLKB1 (0.46) | KLKB1F10 | |
| SCHEMBL20446606 | 0.92 | KLKB1 (0.45) | KLKB1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL20584684 | 0.92 | KLKB1 (0.45) | KLKB1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL31456805 | 0.92 | KLKB1 (0.45) | KLKB1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL21726624 | 0.91 | KLKB1 (0.43) | KLKB1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562850-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562850-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | KLKB1 1/4885F10 109/4885CYP1A2 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.